Thyroid diagnostic enters U.S. market

Article

Draximage of Mississauga, ON, has won FDA approval to market sodium iodide I-131 to evaluate metastases associated with thyroid cancer. The company already markets stronger therapeutic doses of the radioactive agent.

Draximage of Mississauga, ON, has won FDA approval to market sodium iodide I-131 to evaluate metastases associated with thyroid cancer. The company already markets stronger therapeutic doses of the radioactive agent.

The lower strength I-131 capsules, which were approved by the FDA in early January, are designed to gauge the uptake of radioactive iodide as an indicator of thyroid function prior to treatment. In this way, physicians can calculate the therapeutic dose of iodine, according to the company.

The move into diagnostics is the latest in a strategic redirection by Draximage, which last year discontinued the manufacture and sale of implantable brachytherapy seeds. The Canadian firm has since focused its portfolio on sodium iodide I-131 capsules and oral solution for the diagnosis and treatment of thyroid cancer and hyperthyroidism.

A primary offering is its HiCon kit, a large-format kit for the preparation of therapeutic sodium iodide I-131. The kit, introduced in 2003, provides radiopharmacists with empty gelatin capsules and filler material needed to construct a therapeutic dose of radioactive iodine.

"The radiopharmacist has the ability to custom titrate these capsules for each individual patient," said Jerry Ormiston, executive director of investor relations at Draximage.

Draximage sales account for 40% to 50% of the U.S. market for radioactive iodine, which is prescribed for patients with thyroid cancer and parathyroidism. The diagnostic capsules and HiCon kits provide ancillary means to further penetrate that market.

The company also markets a line of lyophilized technetium-99m kits. These are nonradioactive kits used in the preparation of diagnostic doses of technetium.

The company exited the brachytherapy marketplace late last year because the radioactive iodine seeds the company sold for use in therapy against prostate cancer had been commoditized, according to Ormiston.

"Brachytherapy is growing in terms of the number of treated patients, but pricing has been driven down by competition," he said. "You need a much larger volume to be profitable."

To minimize the chance of supply disruptions for its customers, Draximage established a customer supply alternative with Oncura, one of the leading suppliers of prostate brachytherapy products.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.